Salute e Benessere
DNA Synthesis Inhibitors Market Gains Momentum with Growing Adoption in Oncology and Virology | DelveInsight
Discover which indication is expected to grab the major DNA synthesis inhibitors market share @
DNA-synthesis inhibitors remain core components of many chemotherapy regimens and are being actively explored in therapies for genetic disorders and other proliferative diseases. The growing global cancer burden and expanding use of targeted combination therapies are major demand drivers for new and existing DNA-synthesis inhibitors.
Faster, cheaper DNA synthesis, high-throughput screening, improved structural biology, and better in-vitro/in-vivo models let companies design and test DNA-targeting molecules more quickly and cheaply, shortening lead times and increasing the number of viable candidates. This technology tailwind expands the addressable market for inhibitors.
The anticipated launch of promising DNA synthesis inhibitors such as (AiCuris), (Merck), (Nucana BioMed), (Carna Bioscience), and others will propel the market in the coming years.
Currently, a few DNA synthesis inhibitors such as , , and others are approved by the US FDA for the treatment of HIV infections. Gilead Sciences' BIKTARVY is a complete treatment regimen for HIV-1, combining bictegravir, an integrase strand transfer inhibitor (INSTI), with the nucleoside reverse transcriptase inhibitors emtricitabine and tenofovir alafenamide. Initially approved in February 2018 , it was indicated for adults who were either treatment-naïve or virologically suppressed on a stable regimen. In April 2024 , the FDA expanded BIKTARVY's label to include clinical trial results from Study 5310, which demonstrated its safety and efficacy in pregnant adults with HIV-1 and suppressed viral loads. With this update, BIKTARVY became the second-generation INSTI-based single-tablet regimen to receive FDA approval for use in pregnancy. The U.S. Department of Health and Human Services (DHHS) perinatal guidelines now list it as an alternative regimen during pregnancy and recommend its continuation in patients who remain virologically suppressed after becoming pregnant.
In March 2025 , Gilead shared new findings at the Conference on Retroviruses and Opportunistic Infections (CROI), showing that BIKTARVY provided strong dual viral suppression in adults co-infected with HIV and HBV. In the open-label extension of the ALLIANCE study, after switching from DTG + F/TDF to BIKTARVY following 96 weeks of prior therapy, 95.4% of participants achieved HIV RNA <50 copies/mL, while 86.6% reached HBV DNA <29 IU/mL.
Learn more about the DNA synthesis inhibitors @
(Pritelivir), (Ifinatamab Deruxtecan), (NUC‑3373), and several other companies are currently engaged in the development and production of DNA synthesis inhibitors, which have the potential to impact and enhance the DNA synthesis inhibitor market significantly.
is a proprietary Phase III therapeutic candidate granted Breakthrough Therapy designation (BTD) by the US FDA, designed to block HSV replication. Unlike conventional antivirals such as acyclovir, it inhibits the viral helicase-primase complex, a key enzyme in HSV DNA synthesis, making it effective against both HSV-1 and HSV-2, including drug-resistant strains. This novel mechanism offers a vital treatment option for immunocompromised patients who no longer respond to standard therapies.
Clinical studies have confirmed pritelivir's strong efficacy and favorable pharmacokinetics. A pivotal Phase III trial is ongoing to assess its effectiveness in acyclovir-resistant HSV infections among immunocompromised patients. In parallel, AiCuris provides access to pritelivir through Early Access Programs (EAPs), ensuring that eligible patients in urgent need, who have exhausted all available therapies, can receive treatment in a controlled and ethical manner.
According to AiCuris' company presentation, pritelivir is expected to launch in for immunocompromised patients, addressing the unmet need of nearly severely immunocompromised individuals in the US. Differentiating from standard nucleoside analogs, pritelivir offers favorable bioavailability, once-daily oral dosing, a superior safety profile compared to foscarnet, and a lower resistance risk than acyclovir.
is an investigational antibody-drug conjugate (ADC) composed of a humanized anti-B7-H3 IgG1 monoclonal antibody linked to a topoisomerase I inhibitor payload. Co-developed with Daiichi Sankyo, it is in Phase III trials for small cell lung cancer (SCLC; NCT06203210) and Phase II trials for breast cancer (NCT06330064). The candidate is also being explored across multiple additional tumor types, showing potential as a targeted approach to deliver potent chemotherapy directly to cancer cells.
The anticipated launch of these emerging therapies are poised to transform the DNA synthesis inhibitors market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the DNA synthesis inhibitors market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
To know more about DNA synthesis inhibitors clinical trials, visit @
DNA synthesis inhibitors are compounds that disrupt the replication process of DNA, thereby suppressing cell growth or viral multiplication. They are applied in diverse therapeutic areas such as oncology, infectious diseases, and virology. These agents include nucleoside and nucleotide analogs, which integrate into DNA chains and terminate elongation, as well as non-nucleoside molecules that impair polymerase function. Some inhibitors act on enzymes critical for DNA synthesis. For example, thymidylate synthase inhibitors like 5-fluorouracil block thymidine production, an essential nucleotide for DNA replication. Another target is CDC7 kinase, a pivotal regulator that enables DNA replication initiation at origins during the S phase of the cell cycle.
The DNA synthesis Inhibitors market report is a comprehensive and specialized analysis, offering in-depth epidemiological insights for the study period 2020–2034 across the leading markets. In 2024, the United States reported the highest incidence of malignant pleural mesothelioma with nearly cases, representing around of the total cases across the 7MM countries.
The DNA synthesis Inhibitors target patient pool is segmented into:
Discover more about DNA synthesis inhibitors in development @
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key MPM companies including among others.
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key HIV-1 companies, including among others.
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key herpes simplex companies, including among others.
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key breast cancer companies, including among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/dna-synthesis-inhibitors-market-gains-momentum-with-growing-adoption-in-oncology-and-virology--delveinsight-302569233.html